Access at: www.CFRjournal.com Heart failure (HF) is increasing in prevalence globally, and is associated with considerable ill health, healthcare costs and mortality. Prevalence increases steeply with age, and the average age of a person admitted to hospital with decompensation in developed countries such as the UK is in the high 70s.
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What is Telemonitoring?
Telemonitoring or RM encompasses the use of audio, video and other telecommunication technologies to monitor patient status at a distance. 12 Examples include:
• Structured telephone support for patients from the HF team, typically provided by HF specialist nurses as part of a disease management programme or a post-discharge service.
• Standalone devices for use at home which can measure, e.g.
blood pressure, heart rate, weight and oxygen saturation (often supplemented by automated questions on a variety of symptoms).
Trends in these data or movement of any one variable outside preset limits may be used by the HF team to trigger a variety of actions, including a telephone call or clinic review for further assessment, or recommendations on lifestyle and medication changes, or even urgent admission to hospital ( Figure 1 ).
• Cardiac implantable electronic devices, which can provide useful physiological data to aid HF management, either as a dedicated implant to monitor haemodynamics, or a part of the wealth of physiological data recorded by devices such as pacemakers and ICDs, implanted primarily for therapeutic purposes.
• Most recently, a range of wearable technologies, including patches, watches or textiles that can monitor, e.g. ECG, body temperature, blood glucose concentration and body posture.
Evidence for the Benefit of Telemonitoring Technologies
Telephone Support
This was one of the earliest methods of RM to be adopted. Patients were called by a member of the HF team to discuss their symptoms hospitalisation rates compared with usual care (Figure 2) . 13, 14 However, one of the largest randomised trials of telephone-based HF monitoring (Tele-HF) in the US does not support such an approach. 15 In this study, 1,653 patients were randomised to usual care or a telephone-based interactive voice-response system (Tel-Assurance™, Pharos Innovations), which patients dialled into and were then asked to respond to questions about their symptoms and weight, with the results reviewed by their clinician. There was no significant difference in the primary endpoint of death or hospitalisation within 180 days of enrolment, which occurred in 51.5% and 52.3% of patients respectively (p=0.75). It was also noted that 14% of patients randomised to the intervention never used it and, by the final week of the study, only half of them were still using the system three times per week as instructed. As is often the case with telemonitoring technologies, the initial results from a single highly engaged centrethe initial pilot study showed a 44% decrease in hospitalisation -could not be reproduced when the system was expanded into a much larger, multicentre programme. Nevertheless, telephone support for patients in a HF programme remains central to many services, but is generally targeted at more unstable patients, those who have recently returned home after an admission for HF or who live at some considerable distance from the HF service.
Standalone Telemonitoring Systems
Standalone systems allow patients, usually in their own homes, to send noninvasively measured data to their healthcare team, by either telephony-based systems or the internet. In many countries, internet access is wireless, and may be via mobile telecommunication networks. The HF team review the data on a regular basis (usually looking for trends over several days) or can be sent an alert if any variable falls outside a preset limit. Action based on the data can be taken at the healthcare professional's discretion, or there may be a local guideline or protocol that has to be followed. 16 One of the earliest randomised studies was the Trans-European Network -Home-Care Management System study (TEN-HMS). 17 This study recruited 426 patients with HF with reduced ejection fraction (HFrEF) from across Europe, and randomised them in a 2:2:1 ratio to home telemonitoring with a standalone system, nurse telephone support or usual care. The primary outcome of days lost to death or hospitalisation was not different between the groups, but there was a reduction in the length of hospital stay for the home telemonitoring group and lower mortality in the telephone support and telemonitoring patients compared to usual care. Meta-analysis with other (small) studies suggested mortality benefit and a reduction in HF (but not allcause) hospitalisation ( Figure 3 ).
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The first Telemedical Interventional Monitoring in HF (TIM-HF) study with centralised RM run from a telemonitoring centre in Berlin failed to demonstrate any improvement in outcomes in 710 patients randomised and followed up for a minimum of 12 months. 18 However, the larger, follow-on randomised study in 1,571 patients (which required patients to have had a HF hospitalisation in the 12 months preceding enrolment and no evidence of major depression), using a wireless system with a digital tablet to send daily transmissions of 
weight, blood pressure, heart rate, ECG, oxygen saturation and health status questionnaire, reported a borderline statistically significant reduction of just under 7 days in the number of days lost due to unplanned cardiovascular hospital admissions or death compared to the control group (17.8 versus 24.2 days per year, p=0·046). 19 There was also a significant decrease in the secondary endpoint of all-cause mortality, but not cardiovascular mortality.
Outside this centralised 24/7 telemonitoring service in Germany, other large randomised trials have failed to show benefit. In a study in academic centres in California, an RM approach combined with intensive coaching of patients did not show any improvement in mortality or hospitalisation over a 6-month period. 20 In the UK, the Whole System Demonstrator project involved the remote exchange of data between 3,230 patients with diabetes, chronic obstructive pulmonary disease or HF in 179 general practices over 1 year in three areas in England. After adjustment for baseline differences, there was a statistically significant reduction in mortality and length of stay for those hospitalised, but no difference in emergency admission rates for those remotely monitored. 21 Overall savings to the healthcare system were small (geometric mean £242 per patient) and cost-effectiveness was poor.
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Remote Monitoring Through Therapeutic Cardiac Implantable Electronic Devices
The past decade has seen a revolution in the use of remote monitoring of therapeutic devices, such as pacemakers and defibrillators. RM is now standard in many centres for device function and safety reasons. 23, 24 For patients with HF, remote monitoring offers the additional possibility of detecting decompensation earlier.
One of the first intrathoracic technologies developed was Optivol™ (Medtronic), a measure of intrathoracic impedance that is undertaken by direct measurement between the RV lead and pulse generator of the device. The Medtronic Impedance Diagnostics in Heart Failure Trial (Mid-HEFT) was a prospective, observational study investigating the use of intrathoracic impedance as a marker of HF deterioration.
Of the 33 patients who had the device implanted, 10 patients had 25 hospitalisations over the course of 21 months' follow-up. 25 Retrospective review of the impedance data showed a decrease in the 2 weeks preceding HF hospitalisation, well in advance of the symptoms. There was also an increase in intrathoracic impedance as patients underwent diuresis.
This early promise was not confirmed with subsequent larger trials of the technology. Using an alert system to identify when the Optivol score had increased above a predefined threshold that suggested HF deterioration, the Diagnostic Outcome Trial in Heart Failure (DOT-HF) study randomised 335 patients to management with physician and patient access to alerts, or not. The alert arm saw a 79% increase (p=0.02) in the HF hospitalisation rate. 26 Overall, the specificity of the alert system was not acceptable, particularly in the early period after implantation, leading to a high false positive rate and increased hospital admission by the physicians caring for the patients. which patients are at risk of hospitalisation. 28, 29 To date, the Remote Management of Heart Failure Using Implantable
Electronic Devices study (REM-HF) is the largest prospective randomised clinical trial conducted on RM through implanted devices. 30 In this trial, incorporates heart sounds, respiratory rate, heart rate, activity levels and intrathoracic impedance to generate a 'HeartLogic' score. 32 The algorithm uses the patient as their own control, calculating changes from baseline, which removes the need for the clinician to assess the different data streams for all patients. Using a preset threshold provides a 70% sensitivity for identifying a HF event (e.g. one that requires HF hospitalisation or IV therapy) with an unexplained alert rate of 1.5 per patient-year. The alert gives a median lead time before a HF event of 34 days, with 90% of patients being alerted 2 weeks before an event.
The Multiple Cardiac Sensors for the Management of Heart Failure (MANAGE-HF) trial, a large, multicentre outcome study recruiting 2,700 patients, is under way to test whether HeartLogic alert-based management can improve mortality and morbidity from HF when used in more routine care (NCT03237858).
Remote Monitoring Through Implantable Haemodynamic Monitors
Implantable devices offer an opportunity to assess disturbances in haemodynamic parameters promptly, rather than relying on the measurement of less direct measures of HF decompensation which may take longer to become abnormal. Left ventricular filling pressure may be the best measure of the control of the HF syndrome, and several technologies have been developed to measure this directly or indirectly. The aim is to then optimise therapy to maintain filling pressure within an optimal range. Meta-analysis of published studies suggests benefit in preventing hospitalisation (Figure 4) . 33 The Chronicle™ implantable haemodynamic monitor (Medtronic) was designed as a subcutaneous device with a transvenous sensor, much like a pacing lead, that could be deployed in the right ventricular (RV) outflow track, measuring RV pressures to estimate pulmonary artery diastolic pressures, alongside recording heart rate, temperature and physical activity. The subcutaneous device transmitted information intermittently to a home monitor, which would upload the information to a remote server for clinicians to review. The Chronicle Offers
Management to Patients with Advanced Signs and Symptoms of
Heart Failure (COMPASS-HF) study randomised 274 patients who had the device implanted to receive optimal medical care guided by the device (n=134) or a control group with optimal care alone (n=140). to introduce RM, as it may just increase the non-contact workload while reducing income from face-to-face clinical reviews. Figure 1 shows a schema that illustrates some of the key issues that require discussion before a remote monitoring service is established. Very recently, key national and international organisations, as well as health policy-makers, have recognised the challenges around bringing digital technologies into the healthcare system. 43 It is likely that only co-ordinated efforts from all the key stakeholders, including patients themselves, will allow the value of particular technologies to be established.
However, the potential is enormous. If we look at how diabetes is managed, we can see a model where people living with the condition rarely have to seek professional assistance, and how their blood glucose concentrations can easily be incorporated into data platforms that can be accessed by patients, their carers and their healthcare professionals at any point in time and from anywhere there is internet access to the cloud-based server. 44 For those requiring insulin, there are now patches that monitor blood glucose every few minutes, and wirelessly communicate with an insulin pump to help ensure stable blood glucose control. 45 We are far from this situation for HF, which may intrinsically be a more complex syndrome but, undoubtedly, RM will find an important place for those living with HF and the professionals advising them.
